CRXT Annual CFF
$62.99 M
+$15.77 M+33.40%
31 December 2021
Summary:
As of February 5, 2025, CRXT annual cash flow from financing activities is $62.99 million, with the most recent change of +$15.77 million (+33.40%) on December 31, 2021. During the last 3 years, it has risen by +$15.77 million (+33.40%).CRXT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRXT Quarterly CFF
$27.54 M
+$27.54 M+100.00%
30 June 2022
Summary:
As of February 5, 2025, CRXT quarterly cash flow from financing activities is $27.54 million, with the most recent change of +$27.54 million (+100.00%) on June 30, 2022. Over the past year, it has increased by +$9.72 million (+54.56%).CRXT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRXT TTM CFF
$65.53 M
+$9.72 M+17.42%
30 June 2022
Summary:
As of February 5, 2025, CRXT TTM cash flow from financing activities is $65.53 million, with the most recent change of +$9.72 million (+17.42%) on June 30, 2022. Over the past year, it has increased by +$40.53 million (+162.12%).CRXT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRXT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +33.4% | +54.6% | +162.1% |
| 3 y3 years | +33.4% | - | - |
| 5 y5 years | +33.4% | - | - |
CRXT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | at high | at high | at high |
Clarus Therapeutics Holdings Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2022 | - | $27.54 M(>+9900.0%) | $65.53 M(+17.4%) |
| Mar 2022 | - | $0.00(-100.0%) | $55.81 M(-11.4%) |
| Dec 2021 | $62.99 M | $13.80 M(-43.0%) | $62.99 M(+28.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $24.19 M(+35.8%) | $49.19 M(+96.8%) |
| June 2021 | - | $17.82 M(+148.0%) | $25.00 M(+248.0%) |
| Mar 2021 | - | $7.18 M | $7.18 M |
| Dec 2020 | $47.22 M | - | - |
FAQ
- What is Clarus Therapeutics Holdings annual cash flow from financing activities?
- What is the all time high annual CFF for Clarus Therapeutics Holdings?
- What is Clarus Therapeutics Holdings annual CFF year-on-year change?
- What is Clarus Therapeutics Holdings quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Clarus Therapeutics Holdings?
- What is Clarus Therapeutics Holdings quarterly CFF year-on-year change?
- What is Clarus Therapeutics Holdings TTM cash flow from financing activities?
- What is the all time high TTM CFF for Clarus Therapeutics Holdings?
- What is Clarus Therapeutics Holdings TTM CFF year-on-year change?
What is Clarus Therapeutics Holdings annual cash flow from financing activities?
The current annual CFF of CRXT is $62.99 M
What is the all time high annual CFF for Clarus Therapeutics Holdings?
Clarus Therapeutics Holdings all-time high annual cash flow from financing activities is $62.99 M
What is Clarus Therapeutics Holdings annual CFF year-on-year change?
Over the past year, CRXT annual cash flow from financing activities has changed by +$15.77 M (+33.40%)
What is Clarus Therapeutics Holdings quarterly cash flow from financing activities?
The current quarterly CFF of CRXT is $27.54 M
What is the all time high quarterly CFF for Clarus Therapeutics Holdings?
Clarus Therapeutics Holdings all-time high quarterly cash flow from financing activities is $27.54 M
What is Clarus Therapeutics Holdings quarterly CFF year-on-year change?
Over the past year, CRXT quarterly cash flow from financing activities has changed by +$9.72 M (+54.56%)
What is Clarus Therapeutics Holdings TTM cash flow from financing activities?
The current TTM CFF of CRXT is $65.53 M
What is the all time high TTM CFF for Clarus Therapeutics Holdings?
Clarus Therapeutics Holdings all-time high TTM cash flow from financing activities is $65.53 M
What is Clarus Therapeutics Holdings TTM CFF year-on-year change?
Over the past year, CRXT TTM cash flow from financing activities has changed by +$40.53 M (+162.12%)